Intralipid


Also found in: Wikipedia.

Intralipid

 [in″trah-lip´id]
trademark for an intravenous fat emulsion used to prevent or correct deficiency of essential fatty acids and to provide calories in high density form during total parenteral nutrition.

fat emulsion

(fat ee-mul-shun) ,

Intralipid

(trade name),

Liposyn III

(trade name)

Classification

Therapeutic: caloric sources
Pregnancy Category: C

Indications

Provision of nonprotein calories to patients whose total caloric needs cannot be met by carbohydrates (glucose) alone, usually as part of parenteral nutrition.Treatment and prevention of essential fatty acid deficiency in patients receiving long-term parenteral nutrition (provides linoleic acid).

Action

Acts as a nonprotein calorie source.

Therapeutic effects

Provision of essential fatty acids and nonprotein calories.

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.
Distribution: Distributes into intravascular space.
Metabolism and Excretion: Cleared by conversion to triglycerides, then to free fatty acids and glycerol by lipoprotein lipase. Free fatty acids are transported to tissues, where they may be oxidized as an energy source or re-stored as triglycerides.
Half-life: 30–60 min.

Time/action profile

ROUTEONSETPEAKDURATION
IVunknownunknownunknown

Contraindications/Precautions

Contraindicated in: Hyperlipidemias; Lipoid nephrosis; Pancreatitis accompanied by lipemia; Hypersensitivity to egg products (emulsifier is egg yolk phospholipid), legumes, soybeans, or fat emulsions.
Use Cautiously in: Thromboembolic disorders; Severe liver or pulmonary disease; Anemia or bleeding disorders; Patients who are at risk for fat embolism.
Exercise Extreme Caution in: Preterm infants (↓ ability to clear fat emulsion).

Adverse Reactions/Side Effects

Seen only with long-term use.†

Cardiovascular

  • chest pain

Respiratory

  • intravascular fat accumulation(preterm infants only) (life-threatening)

Gastrointestinal

  • hepatomegaly†
  • jaundice†
  • nausea
  • pancreatitis
  • vomiting

Local

  • phlebitis at IV site (most frequent)

Endocrinologic

  • hypertriglyceridemia

Miscellaneous

  • fever (most frequent)
  • infection (most frequent)
  • chills
  • hypersensitivity reactions

Interactions

Drug-Drug interaction

Concurrent use with propofol may ↑ risk of hypertriglyceridemia.

Route/Dosage

Total Parenteral Nutrition
Intravenous (Adults) Initial dose: 1 g/kg/day, increase by 0.5–1 g/kg/day to a maximum of 2.5 g/kg/day.
Intravenous (Children ≥1 mo) Initial dose: 0.5–1 g/kg/day, increase by 0.5 g/kg/day to amaximum of 3 g /kg/day.
Intravenous (Neonates premature) Initial dose: 0.25–0.5 g/kg/day, increase by 0.25–0.5 g/kg/day to a maximum of 3 g/kg/day.
Essential Fatty Acid Deficiency
Intravenous (Adults and Children) Provide 8–10% of caloric intake as fat, infuse once or twice weekly.

Availability

Emulsion for IV Use: 10%, 20%, 30%

Nursing implications

Nursing assessment

  • Monitor weight every other day in adults and daily in infants and children receiving fat emulsion to assist in meeting caloric requirements.
  • Assess patient for allergy to eggs prior to therapy. Acute hypersensitivity reaction with pruritic urticaria may occur in patients allergic to eggs.
  • Lab Test Considerations: Monitor triglyceride and fatty acid levels routinely to determine patient’s capacity to eliminate infused fat from the circulation. Lipemia must clear between daily infusions.
    • Monitor hemoglobin, blood coagulation, and platelet count weekly, especially during continuous therapy. Report abnormalities promptly. Therapy may be discontinued.
    • Monitor serum bilirubin, cholesterol, and hepatic function weekly, especially in premature infants to prevent hyperlipidemia.
  • If signs of overloading syndrome (focal seizures, fever, leukocytosis, splenomegaly, shock) or elevated triglyceride or free fatty acid levels occur, infusion should be stopped and the patient re-evaluated prior to reinstituting therapy.

Potential Nursing Diagnoses

Imbalanced nutrition: less than body requirements (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)

Implementation

  • Intravenous Administration
  • Fat emulsion should comprise no more than 60% of patient’s total caloric intake. The remaining 40% should consist of carbohydrates and amino acids.
    • Fat emulsion may be administered via peripheral or central venous catheter. Monitor peripheral sites for phlebitis.
    • Infuse fat emulsion via Y-site near the infusion site. Because of the lower specific gravity, the fat emulsion solution must be hung higher than the amino acid and dextrose solutions to prevent the fat emulsion from backing up into the amino acid and dextrose line.
    • Manufacturer does not recommend use of filters during administration, but 1.2-micron filters have been used.
    • Use tubing provided by the manufacturer. Change IV tubing after each dose of fat emulsion.
  • Intermittent Infusion: Emulsions that appear oily or that have separated should not be used.30% emulsions must not be infused directly.
    • Pediatric: Avoid use of 10% emulsion in preterm infants; a greater accumulation of plasma lipids occurs due to the greater phospholipid load of the 10% emulsion.
    • Maximum hang times for fat emulsion alone or for admixtures with dextrose and amino acids is 24 hr. Discard all unused portions.
  • Rate: For adults, the initial infusion rate should be 1 mL/min for the 10% solution and 0.5 mL/min for the 20% solution for the first 15–30 min. If no adverse reactions occur, the rate may be increased to infuse 50 mL/hr for the 20% solution or 100 mL/hr for the 10% solution.
    • No more than 500 mL of the 10% solution or 250 mL of 20% solution should be infused at one time.
    • Pediatric: For children, the initial infusion rate should be 0.1 mL/min of the 10% solution and 0.05 mL/min for the 20% solution for the first 10–15 min. If no adverse reactions occur, the rate may be increased to a maximum of 0.25 g/kg/hr.
    • Administer via infusion pump to ensure accurate rate.
  • Y-Site Compatibility: ampicillin, cefazolin, cefoxitin, clindamycin, digoxin, dopamine, erythromycin lactobionate, furosemide, gentamicin, isoproterenol, lidocaine, norepinephrine, oxacillin, penicillin G potassium, tobramycin
  • Y-Site Incompatibility: amikacin
  • Additive Compatibility: Fat emulsion may be admixed (“3-in-1,” all-in-one, triple mix total nutrient admixture [TNA]) or administered simultaneously with amino acid and dextrose solutions, Intralipid is compatible with FreAmine II 8.5%, Travasol without electrolytes 8.5% and 10%, Veinamine 8%, cimetidine, famotidine, hydrocortisone, multivitamins, nizatidine, dextrose 10% and 70%, While not generally recommended, heparin may be added in a concentration of 1–2 units/mL prior to administration to increase clearance rate of lipemia, minimize risks associated with hypercoagulability, and prevent catheter thrombosis
  • Additive Incompatibility: Although compatibility studies have been done, manufacturer recommends that fat emulsion not be admixed with any other medication.

Patient/Family Teaching

  • Explain the purpose of fat emulsion to the patient prior to administration.

Evaluation/Desired Outcomes

  • Weight gain.
    • Maintenance of normal serum triglyceride and fatty acid levels.
References in periodicals archive ?
Due to lack of central venous access, a direct right atrial catheter was inserted at surgery for monitoring and to give parenteral nutrition of intralipid and glucose-amino acid solution.
6 g/L, Intralipid up to 10%, and D-dimer up to 200 mg/L did not alter assay precision.
The LX20 analyzer has the capability to detect hemolysis, icterus, and lipemia in samples and produces semiquantitative unitless index values for hemoglobin, bilirubin, or Intralipid (so-called serum indices), but these serum index functions are not intended for diagnostic purposes.
3) show that samples with added IntraLipid do not perfectly mimic lipemic samples.
We were having our treatment here, and we were doing extras like intralipid drips, which are designed to stop your immune system rejecting the cells.
Finally in November last year, they started the rigorous process again, but this time, scientists decided to combat the Natural Killer Cells by giving Cathy two Intralipid infusions of egg yolk and soya oil, once when the fertilised embryos were put back inside her, and again when she had a positive pregnancy test.
She was given intravenous intralipid therapy, a treatment administered through an IV drip and made from soya bean oil, egg yolk, glycerin and water.
Evidence suggests that intravenous intralipid therapy may enhance embryo implantation, stimulating the immune system to suppress natural killer cells.
Experts at CARE Fertility in Nottingham suggested she tried intralipid infusion therapy - a blend of soya oil and the yolk from a hen's egg taken via a drip.
About a year ago we began evaluating the effect of Intralipid in patients who had Activated Killer Cells.
The use of Intralipid in the management of a mixed overdose.
Previous work has compared preanalyte and postanalyte measurements on the Beckman Synchron LX-20, after artificial spiking of nonlipemic samples with the synthetic lipid Intralipid (Uppsala, Sweden).